Amorphous DMT Polymeric Carrier for Controlled Transmucosal Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic compositions and modes of administration for DMT do not provide optimal therapeutic results for neurological diseases and conditions due to fast onset and short duration of action, complicating the determination of suitable administration regimens and dosage frequency, especially for achieving extended therapeutic blood levels.
Innovation Solution
Development of a pharmaceutical composition comprising amorphous DMT or its pharmaceutically acceptable salt within a polymeric carrier for controlled transmucosal release, using a mucoadhesive polymer matrix with permeation enhancers, buffering agents, and stability enhancers to stabilize DMT and facilitate prolonged therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If DMT is administered via conventional routes (injection or inhalation), then rapid onset of action is achieved, but duration of action is too short for effective therapy of neurological diseases
Solution Approach 1:
The patent segments the DMT delivery process into multiple phases: initial rapid release for quick onset, followed by sustained controlled release for prolonged therapeutic effect. The composition includes different DMT formulations (e.g., DMT fumarate salt for rapid absorption and DMT free base or other salts for sustained release) that release at different rates, thereby resolving the contradiction between fast onset and long duration.
Solution Approach 2:
The patent introduces intermediary substances such as permeation enhancers (e.g., edet disodium edetate, sodium lauryl sulfate), buffering agents (e.g., citrate buffer), and mucoadhesive polymers that facilitate controlled transmucosal release of DMT. These intermediaries enable the DMT to be delivered through the buccal mucosa with both rapid initial absorption and sustained release over time, resolving the contradiction between speed and duration.
2Duration of action of moving object
If DMT is administered to achieve extended therapeutic blood levels, then duration of action is improved, but determination of suitable administration regimen becomes complex
Solution Approach 1:
The patent merges multiple DMT delivery functions into a single composition that provides both rapid onset and sustained release. By combining DMT salts, permeation enhancers, buffering agents, and mucoadhesive polymers in one formulation, the complex task of achieving extended therapeutic levels is simplified into a single administration event rather than multiple dosing regimens.
Solution Approach 2:
The patent utilizes parameter changes in pH and chemical form of DMT to control release kinetics. The buffering agents maintain optimal pH for DMT stability and controlled release, while the combination of DMT salts and free base forms creates different release profiles from a single composition, simplifying the administration regimen while achieving extended therapeutic effects.
3Duration of action of moving object
If amorphous DMT is used in polymeric carrier, then controlled release is achieved, but stability of amorphous form during storage is challenging
Solution Approach 1:
The patent employs composite materials comprising mucoadhesive polymers (e.g., hydroxypropyl cellulose, carbopol), buffering agents (citrate buffer), and permeation enhancers in combination with amorphous DMT. This composite formulation provides a stable matrix that maintains the amorphous state of DMT during storage while enabling controlled release upon administration. The polymeric carrier and buffering agents work synergistically to prevent crystallization and degradation of amorphous DMT.
Solution Approach 2:
The patent introduces intermediary substances such as edet disodium edetate (a chelating agent), sodium lauryl sulfate (a surfactant), and citrate buffer that act as mediators to stabilize amorphous DMT in the polymeric carrier. These intermediaries prevent unwanted phase transitions and chemical degradation, maintaining the stability of the amorphous form during storage while enabling controlled release functionality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition enables controlled and sustained release of DMT, providing a therapeutically effective and stable form for treating neurological diseases and conditions, with improved bioavailability and reduced side effects through transmucosal administration.
Implementation Method 1
controlled transmucosal release of DMT
Implementation Method 2
controlled transmucosal release of DMT suitable for treatment of neurological diseases and conditions
Implementation Method 3
a mucoadhesive polymer matrix with permeation enhancers
Data Source
AI summary
Pharmaceutical compositions including an amorphous N—N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.